

# Pressure BioSciences Inc.

16:23 10 Sep 2019

## Pressure BioSciences' PCT technology highlighted in a pair of medical journal articles

Pressure BioSciences Inc's (OTCMKTS:PBIO) said its signature Pressure Cycling Technology (PCT) platform has been highlighted in a pair of recent medical journal articles.

In a statement on Tuesday, the company noted that teams of scientists in China and Australia published findings that showcased PCT's ability to discover biomarkers associated with cancer in tissue samples preserved from biopsies and highlighted its potential as a diagnostic tool.

Preserved samples, known as formalin-fixed paraffin-embedded (FFPE) samples, are useful for retrospective study of disease progression and therapy responses because the outcomes for the sample's patient is already known.

Pressure's PCT technology helps researchers extract potential cancer biomarkers by employing alternating cycles of hydrostatic pressure to safely control biomolecular interactions.

### READ: Pressure BioSciences wins two more orders for its novel BaroShear K45 water-soluble CBD manufacturing system

The Chinese team from Westlake University in Hangzhou, which has purchased six PCT systems, published an article in 'Molecular Oncology' entitled "High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification."

In the piece, Westlake Laboratory Director Tiannan Guo explained PCT's potential for analyzing the huge backlog of FFPE samples around the world.

"We believe that the vast reservoirs of historical FFPE tissue samples accumulated in biobanks worldwide offer enormous potential using our methods for biomarker discovery, by leveraging the practicality and superiority of PBI's PCT sample preparation platform for maximizing the diversity and abundance of results from FFPE samples," Guo said.

In the other article, from the Australian Cancer Research Center Foundation International Centre for the Proteome of Cancer (ProCan) entitled "Addressing the challenges of high-throughput cancer tissue proteomics for clinical application: ProCan" was published in the journal 'Proteomics'.

Co-director Phil Robinson, who came away impressed with PCT's results, said: "Our results from FFPE tissues following PCT sample preparation are consistent with other reports showing that high quality data can be generated and that the scale and scope of quantifiable proteins is comparable to that obtained from fresh frozen tissues."


The Australian team has purchased six PCT systems since 2016.

Shares of Pressure BioSciences climbed 7.6% higher on Tuesday to \$2.97.

**Price:** \$2.80

**Market Cap:** \$5.43 m

### 1 Year Share Price Graph



September 2018 March 2019 September 2019

### Share Information

**Code:** PBIO

**Listing:** OTCQB

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.03	1.25

**Sector:** Medical technology & services

**Website:** www.pressurebiosciences.com

### Company Synopsis:

*Pressure BioSciences Inc. (OTCQB: PBIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.*

action@proactiveinvestors.com

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to

Twenty	Five	Thousand	dollars	(\$25,000).
--------	------	----------	---------	-------------